Clinical Oncology
Volume 20, Issue 8 , Pages 613-618, October 2008

Non-Hodgkin's Lymphoma of Waldeyer's Ring in Children: Outcome using Chemotherapy and Involved Field Radiotherapy

  • S. Laskar

      Affiliations

    • Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India
    • Corresponding Author InformationAuthor for correspondence: S. Laskar, Department of Radiation Oncology, Tata Memorial Hospital, Dr. Ernest Borges Road, Parel, Mumbai 400012, India. Tel: +91-22-24177167; Fax: +91-22-24146937.
  • ,
  • G. Bahl

      Affiliations

    • Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India
  • ,
  • M.A. Muckaden

      Affiliations

    • Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India
  • ,
  • S. Pai

      Affiliations

    • Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
  • ,
  • R. Nair

      Affiliations

    • Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
  • ,
  • S. Gupta

      Affiliations

    • Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
  • ,
  • T. Shet

      Affiliations

    • Department of Pathology, Tata Memorial Hospital, Mumbai, India
  • ,
  • S. Gujral

      Affiliations

    • Department of Pathology, Tata Memorial Hospital, Mumbai, India
  • ,
  • B. Arora

      Affiliations

    • Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
  • ,
  • M. Sengar

      Affiliations

    • Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
  • ,
  • S.K. Shrivastava

      Affiliations

    • Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India
  • ,
  • K.A. Dinshaw

      Affiliations

    • Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India

Received 6 February 2008; received in revised form 30 April 2008; accepted 6 May 2008.

Abstract 

Aim

To evaluate the prognostic factors and treatment outcome of children with non-Hodgkin's lymphoma (NHL) of Waldeyer's ring treated at a single institution.

Materials and methods

Thirty-two children with NHL of Waldeyer's ring treated at our institute between January 1990 and December 2001 were included in this analysis. The median age at presentation was 14 years, and most of the patients (87%) were boys. The most common histological subtype was diffuse large B-cell lymphoma (75%), 25% patients had stage I and 75% had stage II disease. Treatment comprised a combination of chemotherapy and radiotherapy in most of the patients (75%). Among these patients, 71% received a radiotherapy dose of ≥45Gy.

Results

After a median follow-up of 45 months, the 5-year disease-free and overall survival rates were 76.5 and 83.2%, respectively. Age >10 years (P=0.032), bulky tumours (P=0.001) and the presence of B-symptoms (P=0.004) had a negative influence on disease-free survival. Patients treated with a combination of chemotherapy and radiotherapy had a better outcome than patients treated with chemotherapy alone (disease-free survival: 87.1% vs 56.2%, P=0.056). The complete response (P=0.003), disease-free survival (P=0.001) and overall survival (P=0.001) rates were significantly better for patients receiving a radiotherapy dose ≥45Gy.

Conclusion

The age at diagnosis, the size of the tumour, and the presence of B-symptoms significantly influenced the outcome of children with NHL of Waldeyer's ring in this study. A combined modality treatment, comprising chemotherapy and radiotherapy, resulted in a satisfactory outcome in patients with this rare neoplasm.

Key words: Children, extranodal lymphoma, non-Hodgkin's lymphoma, Waldeyer's ring

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0936-6555(08)00258-6

doi:10.1016/j.clon.2008.05.007

Clinical Oncology
Volume 20, Issue 8 , Pages 613-618, October 2008